Home
Clinical Trials
Study Evaluating DVS-233 SR I...

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Last Updated: 2009-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

480 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2004-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

NCT00073762

Major Depressive Disorder

COMPLETED PHASE3

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

NCT00075257

Major Depressive Disorder

COMPLETED PHASE3

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

NCT00092911

Depression Depressive Disorder Major Depressive Disorder

COMPLETED PHASE3

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

NCT00063206

Major Depressive Disorder

COMPLETED PHASE3

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823

Major Depressive Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DVS-233 SR

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients
* Sexually active women participating in the study must use a medically acceptable form of contraception
* Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria

* Treatment with DVS-233 SR at any time in the past
* Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
* Known hypersensitivity to venlafaxine (IR or ER)

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers